This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide
on smoking behavior, food intake, and weight gain. In this double-blind, placebo-controlled,
parallel arm pilot study, overweight and obese smokers (N=40; 20 female and 20 male) will be
randomized to 32 weeks of liraglutide or placebo and undergo 8 sessions of smoking cessation
behavioral counseling. Outcomes are smoking abstinence and weight change.